| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H21ClN2O4 |
| Molecular Weight | 388.845 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(OCC(=O)N2CCN(CC3=CC=C4OCOC4=C3)CC2)C=C1
InChI
InChIKey=BFUJHVVEMMWLHC-UHFFFAOYSA-N
InChI=1S/C20H21ClN2O4/c21-16-2-4-17(5-3-16)25-13-20(24)23-9-7-22(8-10-23)12-15-1-6-18-19(11-15)27-14-26-18/h1-6,11H,7-10,12-14H2
| Molecular Formula | C20H21ClN2O4 |
| Molecular Weight | 388.845 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CNS Activity
Approval Year
PubMed
Sample Use Guides
Geriatric patients received 600 mg fipexide daily for a period of 3 weeks. Treatment with fipexide was associated with a significant improvement in each and all monitored symptoms and signs to an average extent of 60%, relative to placebo. Overall, 85% of the patients given fipexide experienced clinical improvement to a greater or lesser degree.
Route of Administration:
Oral
Rat and human hepatocytes were incubated with 20 and 100 microM fipexide for 0, 2 and 6 hours at 30 deg-C. Samples were then quenched with equal volumes of ice-cold acetonitrile and centrifuged at 12000 rpm for 10 min at 4 deg-C. The supernatant was diluted 1:1 with water prior to injection into LC/MS to test whether the catechol metabolite or fipexide could be profiled for protein binding.
